https://www.prnewswire.com/news-releases/intarcia-presents-interim-phase-3-data-at-ada-showing-itca-650-a-once-yearly-glp-1-markedly-reduces-blood-sugar-in-patients-with-very-poorly-controlled-diabetes-263201771.html
Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly...
/PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74th Scientific Sessions of the American Diabetes...
https://www.prnewswire.com/news-releases/intarcia-provides-corporate-update-300527104.html
Intarcia Provides Corporate Update
/PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company committed to developing innovative therapies to enhance treatment and...
providescorporateupdate